Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 29;6:237. doi: 10.1038/s41597-019-0255-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the metadata files associated with this article.

PMC Copyright notice

Fig. 1 — Schematic representation of study design. Eight human cancer cell lines from different tissue origins were used in this study. Cells were incubated overnight prior to drug addition. In the primary screen, cells were screened against 19 small-molecule inhibitors in single and double application, with a total of 171 combinations. After 48 hours of drug exposure the assay was terminated, and cell viability was measured using CellTiter-Glo 2.0 (Promega). In the secondary screen, cells were screened against 7 single small-molecule inhibitors and 6 combinations for a duration of 48 hours. Drug effect was measured using automated brightfield imaging of confluency and CellTiter-Glo 2.0 (Promega).